Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Loxapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 known ✓ | P21917 | 6/20 | 0.82 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.82 |
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 0.82 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.82 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.82 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.82 |
| ▸ | HRH1 | P35367 | 4/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxapine SCHEMBL29414130 | 1.00 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL41643 | 1.00 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL30201498 | 1.00 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL29374082 | 0.90 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL29482385 | 0.90 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL94146 | 0.90 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL19386241 | 0.90 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL30324780 | 0.90 | HRH4 (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| Loxapine SCHEMBL41644 | 0.90 | LMNA (0.82) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5946392 | 0.90 | MEN1 (0.81) | LMNAMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1014977-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| EP-1014977-A4 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP LTD (GB) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998007426-A1 | DIAGNOSIS OF MIGRAINE WITH AURA, DEPRESSION AND ANXIETY FROM ALLELIC VARIATIONS IN DOPAMINERGIC GENES | GLAXO GROUP, LTD. (GB) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137853-A1 | METHODS OF TREATING EPILEPTIC PATIENTS WITH FENFLURAMINE | SLC6A4, SLC1A2, SLC6A2 | DRD4 361/4885DRD2 172/4885DRD3 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.